126 related articles for article (PubMed ID: 25764026)
1. Prognostic role of nuclear factor/IB and bone remodeling proteins in metastatic giant cell tumor of bone: A retrospective study.
Quattrini I; Pollino S; Pazzaglia L; Conti A; Novello C; Ferrari C; Pignotti E; Picci P; Benassi MS
J Orthop Res; 2015 Aug; 33(8):1205-11. PubMed ID: 25764026
[TBL] [Abstract][Full Text] [Related]
2. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone.
Mosakhani N; Pazzaglia L; Benassi MS; Borze I; Quattrini I; Picci P; Knuutila S
Histol Histopathol; 2013 May; 28(5):671-8. PubMed ID: 23172052
[TBL] [Abstract][Full Text] [Related]
4. Receptor activator for nuclear factor κ B expression predicts poor prognosis in breast cancer patients with bone metastasis but not in patients with visceral metastasis.
Zhang L; Teng Y; Zhang Y; Liu J; Xu L; Qu J; Hou K; Yang X; Liu Y; Qu X
J Clin Pathol; 2012 Jan; 65(1):36-40. PubMed ID: 22049226
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
[TBL] [Abstract][Full Text] [Related]
6. Denosumab treated giant cell tumour of bone: a morphological, immunohistochemical and molecular analysis of a series.
Girolami I; Mancini I; Simoni A; Baldi GG; Simi L; Campanacci D; Beltrami G; Scoccianti G; D'Arienzo A; Capanna R; Franchi A
J Clin Pathol; 2016 Mar; 69(3):240-7. PubMed ID: 26338802
[TBL] [Abstract][Full Text] [Related]
7. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
8. Expression of ezrin, CD44, and VEGF in giant cell tumor of bone and its significance.
Zhang J; Dong J; Yang Z; Ma X; Zhang J; Li M; Chen Y; Ding Y; Li K; Zhang Z
World J Surg Oncol; 2015 May; 13():168. PubMed ID: 25929323
[TBL] [Abstract][Full Text] [Related]
9. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
10. Expression of receptor activator of nuclear factor kappa-B as a poor prognostic marker in breast cancer.
Park HS; Lee A; Chae BJ; Bae JS; Song BJ; Jung SS
J Surg Oncol; 2014 Dec; 110(7):807-12. PubMed ID: 25111682
[TBL] [Abstract][Full Text] [Related]
11. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
12. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
13. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
[TBL] [Abstract][Full Text] [Related]
14. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone.
Roux S; Amazit L; Meduri G; Guiochon-Mantel A; Milgrom E; Mariette X
Am J Clin Pathol; 2002 Feb; 117(2):210-6. PubMed ID: 11863217
[TBL] [Abstract][Full Text] [Related]
15. Denosumab: a new treatment option for giant cell tumor of bone.
Lewin J; Thomas D
Drugs Today (Barc); 2013 Nov; 49(11):693-700. PubMed ID: 24308016
[TBL] [Abstract][Full Text] [Related]
16. Markers of bone remodeling in neoplastic and bone-related lesions.
Elias LS; Costa RF; Carvalho MA; Batista AC; Silva TA; Leles CR; Mendonça EF
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Nov; 110(5):624-31. PubMed ID: 20955951
[TBL] [Abstract][Full Text] [Related]
17. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis.
Sasaki A; Ishikawa K; Haraguchi N; Inoue H; Ishio T; Shibata K; Ohta M; Kitano S; Mori M
Ann Surg Oncol; 2007 Mar; 14(3):1191-9. PubMed ID: 17195907
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analyses of beta-catenin and cyclin D1 expression in giant cell tumor of bone (GCTB): a possible role of Wnt pathway in GCTB tumorigenesis.
Matsubayashi S; Nakashima M; Kumagai K; Egashira M; Naruke Y; Kondo H; Hayashi T; Shindo H
Pathol Res Pract; 2009; 205(9):626-33. PubMed ID: 19324500
[TBL] [Abstract][Full Text] [Related]
19. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer.
Russmueller G; Moser D; Würger T; Wrba F; Christopoulos P; Kostakis G; Seemann R; Stadler V; Wimmer G; Kornek G; Psyrri A; Filipits M; Perisanidis C
Oral Oncol; 2015 Mar; 51(3):247-53. PubMed ID: 25532817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]